生物标志物 生物标志物
Garrett B Duncan1, Tyler M Duke1, Samuel B Johnson1
1Pentara Corporation, Salt Lake City, UT, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
化化 (pTau) 生物标志物在预测阿尔茨海默病 (AD) 进展方面,其准确性与昂贵的粉样蛋白PET扫描相美. 这些方便的血液测试提供了更高的灵敏度,并可以实现更小,更具成本效益的临床试验.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默病 (AD) 病理生理学和生物标志物研究正在取得进展.
- 粉样PET是AD试验中的标准诊断工具和结果指标,但它昂贵且资源密集.
- 化的 (pTau) 正在作为一种更容易获得的AD生物标志物进行研究.
研究的目的:
- 在阿尔茨海默病 (AD) 试验中评估血pTau (pT217,pT181) 在预测临床结果和疾病进展方面的准确性和灵敏性.
- 为了比较血pTau生物标志物的实用性与传统的粉样蛋白PET成像.
- 评估血pTau的潜力,作为药物开发早期阶段的主要结果衡量标准.
主要方法:
- 来自抗粉样单克隆抗体 (mAb) 研究的已公布数据的分析.
- 计算等离子体pT217/pT181治疗效果与临床结果之间的小组级皮尔森相关性.
- 血pTau相关性与粉样PET相关性的比较.
- 用于模拟概念验证研究设计和评估样本大小要求的功率计算.
主要成果:
- 血pT217和pT181显示了与粉样PET相比的临床结果的组级相关性.
- 血pT217/pT181的效应大小 (科恩的d) 比标准临床结果评估 (ADAS-Cog,ADCS-ADL,CDR-SB) 的效应大.
- 血pT217/pT181对疾病进展的敏感性增加了3倍,在样本大小的九分之一的情况下实现了可比功率.
结论:
- 血pTau生物标志物 (pT217,pT181) 为预测AD的临床结果提供了一个可靠,具有成本效益和可访问的替代品,而不是粉样蛋白PET.
- 与当前的临床测量相比,这些生物标志物表现出更大的效果大小和更高的疾病进展敏感性.
- 血pTau生物标志物可以促进更小,更有效的阿尔茨海默病药物开发早期临床试验.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511